Interesting NEJM Question / Commentary that was brought to my attention by Biowatch.
Two independent groups cite observations in glioblastoma and NSCLC that patients responsive to Iressa tend to have cytoplasmic expression of EGF-R. It would be interesting if cytoplasmic expression becomes a validated biological finding in these tumours... it would have some consequences in the battle between small molecules and antibodies aimed at EGF-R.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.